sharon sanders
Editor-in-Chief & President
D614G Spike Mutation Increases SARS CoV-2 Susceptibility to Neutralization.
View ORCID Profile
Drew Weissman, Mohamad-Gabriel Alameh, Tushan de Silva, Paul Collini, Hailey Hornsby, Rebecca Brown , Celia C LaBranche, Robert J Edwards, Laura Sutherland, Sampa Santra, Katayou n Mansouri, Sophie Gobeil, Charlene McDanal, Norbe rt Pardi, Nick Hengartner, Paulo J.C. Lin, Ying Tam, Pamela A Shaw, Mark G Lewis, Carsten Boesler, Ugur Sahin, Priyamvada A charya, Barton F Haynes, Bette Korber, David C Montefiori
doi: https://doi.org/10.1101/2020.07.22.20159905
This article is a preprint and has not been peer-reviewed [what does this mean?]. It reports new medical research that has yet to be evaluated and so should not be used to guide clinical practice.
Abstract
The SARS-CoV-2 Spike protein acquired a D614G mutation early in the COVID-19 pandemic that appears to confer on the virus greater infectivity and is now the globally dominant form of the virus. Certain of the current vaccines entering phase 3 trials are based on the original D614 form of Spike with the goal of eliciting protective neutralizing antibodies. To determine whether D614G mediates neutralization-escape that could compromise vaccine efficacy, sera from Spike-immunized mice, nonhuman primates and humans were evaluated for neutralization of pseudoviruses bearing either D614 or G614 Spike on their surface. In all cases, the G614 pseudovirus was moderately more susceptible to neutralization. The G614 pseudovirus also was more susceptible to neutralization by monoclonal antibodies against the receptor binding domain and by convalescent sera from people known to be infected with either the D614 or G614 form of the virus. These results indicate that a gain in infectivity provided by D614G came at the cost of making the virus more vulnerable to neutralizing antibodies, and that the mutation is not expected to be an obstacle for current vaccine development.
Competing Interest Statement
In accordance with the University of Pennsylvania policies and procedures and our ethical obligations as researchers, we report that Drew Weissman is named on patents that describe the use of nucleoside-modified mRNA as a platform to deliver therapeutic proteins. Drew Weissman and Norbert Pardi are also named on a patent describing the use of modified mRNA in lipid nanoparticles as a vaccine platform. We have disclosed those interests fully to the University of Pennsylvania, and we have in place an approved plan for managing any potential conflicts arising from licensing of our patents.
Clinical Trial
NCT04380701
https://www.medrxiv.org/content/10.1101/2020.07.22.20159905v2
View ORCID Profile
Drew Weissman, Mohamad-Gabriel Alameh, Tushan de Silva, Paul Collini, Hailey Hornsby, Rebecca Brown , Celia C LaBranche, Robert J Edwards, Laura Sutherland, Sampa Santra, Katayou n Mansouri, Sophie Gobeil, Charlene McDanal, Norbe rt Pardi, Nick Hengartner, Paulo J.C. Lin, Ying Tam, Pamela A Shaw, Mark G Lewis, Carsten Boesler, Ugur Sahin, Priyamvada A charya, Barton F Haynes, Bette Korber, David C Montefiori
doi: https://doi.org/10.1101/2020.07.22.20159905
This article is a preprint and has not been peer-reviewed [what does this mean?]. It reports new medical research that has yet to be evaluated and so should not be used to guide clinical practice.
Abstract
The SARS-CoV-2 Spike protein acquired a D614G mutation early in the COVID-19 pandemic that appears to confer on the virus greater infectivity and is now the globally dominant form of the virus. Certain of the current vaccines entering phase 3 trials are based on the original D614 form of Spike with the goal of eliciting protective neutralizing antibodies. To determine whether D614G mediates neutralization-escape that could compromise vaccine efficacy, sera from Spike-immunized mice, nonhuman primates and humans were evaluated for neutralization of pseudoviruses bearing either D614 or G614 Spike on their surface. In all cases, the G614 pseudovirus was moderately more susceptible to neutralization. The G614 pseudovirus also was more susceptible to neutralization by monoclonal antibodies against the receptor binding domain and by convalescent sera from people known to be infected with either the D614 or G614 form of the virus. These results indicate that a gain in infectivity provided by D614G came at the cost of making the virus more vulnerable to neutralizing antibodies, and that the mutation is not expected to be an obstacle for current vaccine development.
Competing Interest Statement
In accordance with the University of Pennsylvania policies and procedures and our ethical obligations as researchers, we report that Drew Weissman is named on patents that describe the use of nucleoside-modified mRNA as a platform to deliver therapeutic proteins. Drew Weissman and Norbert Pardi are also named on a patent describing the use of modified mRNA in lipid nanoparticles as a vaccine platform. We have disclosed those interests fully to the University of Pennsylvania, and we have in place an approved plan for managing any potential conflicts arising from licensing of our patents.
Clinical Trial
NCT04380701
https://www.medrxiv.org/content/10.1101/2020.07.22.20159905v2